Study of amivantamab plus chemo for head and neck cancer
Part of Cancer clinical trials.
This trial tests a new drug (amivantamab) combined with two chemotherapy drugs (carboplatin and paclitaxel) for people with head and neck cancer that has spread or come back after treatment and cannot be removed by surgery. This study aims to see if this combination can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell head and neck cancer that has spread, come back, or cannot be removed with surgery.
- You have had prior treatment with a PD-1 or PD-L1 inhibitor (a type of immunotherapy).
- You have not had more than two prior treatments for advanced or metastatic disease.
- You have not had prior treatment with platinum or taxane chemotherapy for advanced disease (unless it was given with radiation and you did not progress for at least 6 months after).
- You are 18 or older, and your overall health is good enough that you can perform daily activities (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the drug amivantamab to usual treatments helps people with advanced head and neck cancer that has come back or spread. It compares the combination to standard care alone.
This trial tests adding amivantamab to standard FOLFIRI chemotherapy for people with certain types of colorectal cancer that have already been treated once. It aims to see if this combination works better than another common treatment (cetuximab or bevacizumab plus FOLFIRI).
This trial tests a drug called amivantamab, either alone or with other treatments, for people with head and neck cancer that has spread or come back. The goal is to see if the drug can help shrink tumors or control the cancer.
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
This study follows patients with advanced lung cancer (a type called non-small cell lung cancer) who are receiving a combination of chemotherapy and a drug called amivantamab. Researchers want to understand how well this treatment works and track your health outcomes over time.
Hear when a new Head &Amp; Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.